Clinical responses to ERK inhibitor (GDC-0994) treatment combinations predicted using a Quantitative Systems Pharmacology model of MAPK signaling in BRAF(V600E)-mutant colorectal cancer
Daniel C. Kirouac(University of Toronto), Saroja Ramanujan(Unknown), Mark Merchant(Revolution Medicines (United States)), L. Liu, Kapil Gadkar(Sea Turtle Conservancy), Gabriele Schaefer(Genesys (United States)), John S.D. Chan(Centre Hospitalier de l’Université de Montréal), John G. Moffat(Biochemical Society), C. Orr, Alan Huang(Tango Therapeutics (United States))
Cited by 2
Related Papers
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
|Science Translational Medicine|2014|373
A Comprehensive Review of Interventions in the NOD Mouse and Implications for Translation
|Immunity|2005|317
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
|Science Translational Medicine|2013|267
A TREM2-activating antibody with a blood–brain barrier transport vehicle enhances microglial metabolism in Alzheimer’s disease models
|Nature Neuroscience|2023|227
CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy
|Cell Reports Medicine|2023|190